Market closedNon-fractional
Nuvalent/NUVL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Nuvalent
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
Ticker
NUVL
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Cambridge, United States
Employees
106
Website
www.nuvalent.com
Nuvalent Metrics
BasicAdvanced
$5.2B
Market cap
-
P/E ratio
-$2.42
EPS
1.35
Beta
-
Dividend rate
Price and volume
Market cap
$5.2B
Beta
1.35
Financial strength
Current ratio
20.926
Quick ratio
20.697
Management effectiveness
Return on assets (TTM)
-18.37%
Return on equity (TTM)
-26.01%
Valuation
Price to book
7.59
Price to tangible book (TTM)
7.59
Price to free cash flow (TTM)
-43.117
Growth
Earnings per share change (TTM)
40.10%
3-year earnings per share growth (CAGR)
-34.77%
What the Analysts think about Nuvalent
Analyst Ratings
Majority rating from 10 analysts.
Nuvalent Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$44M
16.23%
Profit margin
0.00%
NaN%
Nuvalent Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.51
-$0.59
-$0.62
-$0.69
-
Expected
-$0.53
-$0.58
-$0.60
-$0.68
-$0.76
Surprise
-3.15%
1.29%
3.18%
1.44%
-
Nuvalent News
AllArticlesVideos
Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor
PRNewsWire·5 days ago
Nuvalent to Present Updated Data for ROS1-Selective Inhibitor, Zidesamtinib, and ALK-Selective Inhibitor, NVL-655, at the ESMO Congress 2024
PRNewsWire·2 weeks ago
Nuvalent Announces Promotion of Henry Pelish, Ph.D. to Chief Scientific Officer
PRNewsWire·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nuvalent stock?
Nuvalent (NUVL) has a market cap of $5.2B as of July 27, 2024.
What is the P/E ratio for Nuvalent stock?
The price to earnings (P/E) ratio for Nuvalent (NUVL) stock is 0 as of July 27, 2024.
Does Nuvalent stock pay dividends?
No, Nuvalent (NUVL) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Nuvalent dividend payment date?
Nuvalent (NUVL) stock does not pay dividends to its shareholders.
What is the beta indicator for Nuvalent?
Nuvalent (NUVL) has a beta rating of 1.35. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Nuvalent stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.